In our studies, we found that modulation of the EMT status of cancer cells by perturbing the ZEB1/miR-200 axis led to CDK4 pathway modulation and determined the sensitivity to CDK4 inhibitors both in vitro and in vivo. Here, ZEB1 is linked to cancer.